GB943121A - Medicines containing lactones from piper methysticum - Google Patents

Medicines containing lactones from piper methysticum

Info

Publication number
GB943121A
GB943121A GB1881161A GB1881161A GB943121A GB 943121 A GB943121 A GB 943121A GB 1881161 A GB1881161 A GB 1881161A GB 1881161 A GB1881161 A GB 1881161A GB 943121 A GB943121 A GB 943121A
Authority
GB
United Kingdom
Prior art keywords
mixture
methysticin
yangonin
kawa
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1881161A
Inventor
Josef Nickl
Johannes Keck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Priority to GB1881161A priority Critical patent/GB943121A/en
Publication of GB943121A publication Critical patent/GB943121A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition having sedative and anti-convulsive action comprises as active ingredient a mixture consisting of 20-75% yangonin and 80-25% methysticin. Preferred mixtures consist of 25-40% yangonin and 75 to 60% methysticin. The mixture may be prepared by extracting Piper methysticum (Radix Kawa-Kawa) with methylene chloride, followed by concentration of the extract, mixing with alumina, filtering, removing the solvent from the filtrate and taking up the residue with ether. The residue remaining after removing the ether solution is the desired mixture. Alternatively, pure yangonin and methysticin (isolated by known methods) may be used. The mixture may be put up in various pharmaceutical dosage forms containing 50 to 500 mg. of active ingredient, e.g. tablets, capsules, dragees, suppositories and aqueous or oily injections. Optional ingredients are (a) sedatives, e.g. phenylethyl barbituric acid; (b) tranquillizers, e.g. 2 - methyl - 2 - n - propyl - 1,3 - propanediol dicarbamate; and (c) central nervous system depressants, e.g. 3-chloro-10(g -dimethylaminopropyl)-phenthiazine.
GB1881161A 1961-05-24 1961-05-24 Medicines containing lactones from piper methysticum Expired GB943121A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1881161A GB943121A (en) 1961-05-24 1961-05-24 Medicines containing lactones from piper methysticum

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1881161A GB943121A (en) 1961-05-24 1961-05-24 Medicines containing lactones from piper methysticum

Publications (1)

Publication Number Publication Date
GB943121A true GB943121A (en) 1963-11-27

Family

ID=10118814

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1881161A Expired GB943121A (en) 1961-05-24 1961-05-24 Medicines containing lactones from piper methysticum

Country Status (1)

Country Link
GB (1) GB943121A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004036A1 (en) * 1990-09-12 1992-03-19 Dr. Willmar Schwabe Gmbh & Co. Kava extract, method of preparing the extract, and its use
EP0523591A2 (en) * 1991-07-15 1993-01-20 Dr. Willmar Schwabe GmbH & Co. Use of a Kava extract and of its constituents
US5296224A (en) * 1990-09-12 1994-03-22 Dr. Wilmar Schwabe Gmbh & Co. Kava-kava extract, process for the production thereof and use thereof
WO2004030684A2 (en) * 2002-10-03 2004-04-15 Herbal Science, Llc Kavalactone product
US7029707B2 (en) 2001-10-03 2006-04-18 Herbalscience, Llc Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
US7037524B2 (en) 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US7105185B2 (en) 2001-10-03 2006-09-12 Herbalscience, Llc Kavalactone profile
US7279184B2 (en) 2003-10-24 2007-10-09 Herbalscience, Llc Methods and compositions comprising Ilex
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US7294353B2 (en) 2003-10-24 2007-11-13 Herbalscience, Llc Methods and compositions comprising ilex

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004036A1 (en) * 1990-09-12 1992-03-19 Dr. Willmar Schwabe Gmbh & Co. Kava extract, method of preparing the extract, and its use
US5296224A (en) * 1990-09-12 1994-03-22 Dr. Wilmar Schwabe Gmbh & Co. Kava-kava extract, process for the production thereof and use thereof
EP0523591A2 (en) * 1991-07-15 1993-01-20 Dr. Willmar Schwabe GmbH & Co. Use of a Kava extract and of its constituents
EP0523591A3 (en) * 1991-07-15 1993-03-31 Dr. Willmar Schwabe Gmbh & Co. Use of a kava extract and of its constituents
US7001620B2 (en) 2001-10-03 2006-02-21 Herbal Science, Llc Kavalactone product
US7029707B2 (en) 2001-10-03 2006-04-18 Herbalscience, Llc Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
US7037524B2 (en) 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US7105185B2 (en) 2001-10-03 2006-09-12 Herbalscience, Llc Kavalactone profile
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
WO2004030684A3 (en) * 2002-10-03 2004-09-23 Herbal Science Llc Kavalactone product
WO2004030684A2 (en) * 2002-10-03 2004-04-15 Herbal Science, Llc Kavalactone product
US7279184B2 (en) 2003-10-24 2007-10-09 Herbalscience, Llc Methods and compositions comprising Ilex
US7294353B2 (en) 2003-10-24 2007-11-13 Herbalscience, Llc Methods and compositions comprising ilex

Similar Documents

Publication Publication Date Title
GB943121A (en) Medicines containing lactones from piper methysticum
ATE49886T1 (en) NEW GALENIC PREPARATION FORMS OF ORAL ANTIDIABETICS AND PROCESSES FOR THEIR MANUFACTURE.
FR2361914A1 (en) NEW FORMULATIONS OF DRUGS WITH REDUCED DANGER OF ABUSIVE USE
FR2356669A1 (en) STEROL SEPARATION PROCESS
ES8504246A1 (en) A thrombolytic agent.
BE1002745A7 (en) COMPOSITION FOR THE PREVENTION OF MEDICAL TREATMENT OF PERIODONTHOPATHY.
KR910005879A (en) Pharmaceutical preparations and methods for producing new anticancer activity
JPS542316A (en) Solid pharmaceutical composition containing nifedipene
RU2000120474A (en) PHARMACEUTICAL COMPOSITION POSSESSING ANTITUM ACTIVITY AND METHOD FOR PRODUCING IT
US4906471A (en) Pharmaceutical composition for the reducing both hyperlipidemia and platelet-aggregation (PHP)
YU67492A (en) PROCEDURE FOR OBTAINING A PHARMACEUTICAL MEDICINAL PRODUCT
JPS61246114A (en) Hair tonic composition
JPS56120621A (en) Preparation of substance having wound remedying action
FR2424277A1 (en) 8B-ETHYL- (OR METHYL) -4,5A-EPOXYMORPHINANE-6-ONES, THEIR PRODUCTION PROCESS AND MEDICINAL PRODUCTS CONTAINING THEM
GB1361223A (en) Process of extracting the unsaponifiable fraction from natural fats
Geiling et al. Variations in blood pressure induced by repeated injections of extracts of the posterior lobe of the pituitary gland
US2074492A (en) Medicinal compound
SU404478A1 (en) EMULSIFIER
JPS5235368A (en) Oil-water separation process
Phillips et al. Further studies on the role of progesterone in the inhibition of estrous cycles in the albino rat
DE651597C (en) Process for the preparation of durable hormone preparations
FR2332760A1 (en) NEW PROCESS FOR EXTRACTING THE EMBRYONARY SKINS OF CALVES, PROTEIN SUBSTANCES OBTAINED, AND COSMETIC AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US2682533A (en) Method of debitterization of cascara sagrada
GB911179A (en) Hypnotic and tranquilizing compositions comprising 4, 6-dimethyl-3-pyridazone
JPH0474334B2 (en)